{
    "clinical_study": {
        "@rank": "93913", 
        "acronym": "PEG-G-CSF", 
        "arm_group": [
            {
                "arm_group_label": "DA-3031", 
                "arm_group_type": "Experimental", 
                "description": "PEG-G-CSF"
            }, 
            {
                "arm_group_label": "Leucostim\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "G-CSF"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to determine whether once-per-cycle DA-3031(PEG-G-CSF) is not inferior to\n      daily G-CSF in chemotherapy-induced neutropenia."
        }, 
        "brief_title": "Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chemotherapy Induced Neutropenia", 
        "condition_browse": {
            "mesh_term": "Neutropenia"
        }, 
        "detailed_description": {
            "textblock": "Eligible subjects are randomly assigned to receive once-per-cycle DA-3031(PEG-G-CSF) or\n      daily G-CSF(up to 10 days). This study is conducted for 6 cycles of chemotherapy, that each\n      cycle is repeated every 21 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age : \u226518, \u226470\n\n          2. Diagnosis of stage II, III or IV breast cancer\n\n          3. ANC\u22651,500/mm3, Platelet\u2265100,000/mm3, ECOG : 0 or 1\n\n          4. Creatinine < 1.5 x ULN\n\n          5. Total bilirubin/AST/ALT < 1.5 x ULN, ALP < 2.5 x ULN\n\n          6. Have given a written, informed consent\n\n        Exclusion Criteria:\n\n          1. Prior chemotherapy\n\n          2. Prior bone marrow or stem cell transplantation\n\n          3. Other malignancy history within 5 years\n\n          4. Prior exposure to pegfilgrastim or filgrastim or other colony-stimulating factors\n\n          5. Received any other investigational drugs within 30 days of informed consent date\n\n          6. Radiation therapy within 4 weeks of informed consent date\n\n          7. Infective symptom before chemotherapy into this study\n\n          8. Received systemic antibiotics within 72 hours of randomization into this study.\n\n          9. HIV positive\n\n         10. Pregnant or lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01674855", 
            "org_study_id": "DA3031_NP_III"
        }, 
        "intervention": [
            {
                "arm_group_label": "DA-3031", 
                "description": "Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle", 
                "intervention_name": "PEG-G-CSF", 
                "intervention_type": "Drug", 
                "other_name": "DA-3031"
            }, 
            {
                "arm_group_label": "Leucostim\u00ae", 
                "description": "Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 6 cycle", 
                "intervention_name": "G-CSF", 
                "intervention_type": "Drug", 
                "other_name": "Leucostim\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Lenograstim"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "PEG-G-CSF", 
        "lastchanged_date": "August 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "152-703"
                }, 
                "name": "Korea University GURO hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Open, Multi-Center, Phase III Study to Evaluate Efficacy and Safety in Chemotherapy-induced Neutropenia of Once-per-cycle DA-3031(PEG-G-CSF) and Daily G-CSF in Patients With Malignancies Receiving Myelosuppressive Chemotherapy", 
        "overall_official": {
            "affiliation": "Korea University Guro Hospital", 
            "last_name": "JaeHong Seo, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Grade 4 neutropenia means the ANC count is less than 500/mm3.", 
            "measure": "Duration of grade 4 neutropenia in cycle 1", 
            "safety_issue": "No", 
            "time_frame": "21 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01674855"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "ANC nadir means the lowest point of ANC count.", 
                "measure": "ANC nadir in cycle 1", 
                "safety_issue": "No", 
                "time_frame": "21 day"
            }, 
            {
                "description": "ANC recovery means the ANC count is more than 2,000/mm3.", 
                "measure": "Time to ANC recovery in cycle 1", 
                "safety_issue": "No", 
                "time_frame": "21 day"
            }, 
            {
                "description": "Febrile neutropenia means the ANC count is less than 1,000/mm3 and body temperature is more than 38.3 degrees celsius.", 
                "measure": "Incidence of febrile neutropenia", 
                "safety_issue": "Yes", 
                "time_frame": "126 day"
            }, 
            {
                "description": "IV antibiotics administration means that antibiotics are administered through intravenous route.", 
                "measure": "Incidence of IV antibiotics administration", 
                "safety_issue": "No", 
                "time_frame": "126 day"
            }
        ], 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}